Posted by Michael Wonder on 24 May 2024
Camurus receives EMA acceptance of MAA filing for octreotide SC depot (CAM2029) for the treatment of acromegaly
23 May 2024 - Camurus today announced that the EMA has accepted for review the company’s marketing authorisation application for octreotide subcutaneous depot (CAM2029) for the treatment of patients with acromegaly.
The acceptance follows the marketing authorisation application submission done end of April 2024 and marks the beginning of the formal review procedure.
